Safety Aspects and Rational Use of Single Intramuscular Dose Ceftriaxone: Clinical Insights on the Management of Uncomplicated Gonococcal Infections

References

• World Health Organization. Multi-drug resistant gonorrhoea. Geneva: World Health Organization; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/multi-drug-resistant-gonorrhoea. Accessed June 16, 2023.
   Google Scholar
• Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2021. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2023. Available from: https://www.cdc.gov/std/statistics/2021/default.htm. Accessed June 16, 2023.
   Google Scholar
• Kirkcaldy RD, Weston E, Segurado AC, Hughes G. Epidemiology of gonorrhoea: a global perspective. Review Sex Health. 2019;16(5):401–411. doi:10.1071/SH19061
   PubMed Web of Science ®Google Scholar
• Rubin HF, Ross JDC, Grad YH. The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae. Transl Res. 2020;220:122–137. doi:10.1016/j.trsl.2020.02.002
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2013. Available from: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed June 17, 2023.
   Google Scholar
• World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: World Health Organization; 2017. Available from: https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12. Accessed June 17, 2023.
   Google Scholar
• Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed June 17, 2023.
   Google Scholar
• Dalke B, Ivers T, O’Brien KK, Castillo S, Hoie E, Begley K. Gonorrhea: treatment and management considerations for the male patient. US Pharm. 2016;41(8):41–44.
   Google Scholar
• Detels R, Green AM, Klausner JD, et al. The incidence and correlates of symptomatic and asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in selected populations in five countries. Sex Transm Dis. 2011;38(6):503–509. doi:10.1097/OLQ.0b013e318206c288
   PubMed Web of Science ®Google Scholar
• Morris SR, Klausner JD, Buchbinder SP, et al. Prevalence and incidence of pharyngeal gonorrhea in a longitudinal sample of men who have sex with men: the EXPLORE study. Clin Infect Dis. 2006;43(10):1284–1289. doi:10.1086/508460
   PubMed Web of Science ®Google Scholar
• Nettleton WD, Kent JB, Macomber K, et al. Ongoing cluster of highly related disseminated gonococcal infections—southwest Michigan, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(12):353–354. doi:10.15585/mmwr.mm6912a5
   PubMed Web of Science ®Google Scholar
• Petro J. Sulphonamide resistance in gonorrhoea. Lancet. 1943;241(6228):35–38. doi:10.1016/S0140-6736(00)89071-6
   Google Scholar
• Kampmeier RH. Introduction of sulfonamide therapy for gonorrhea. Sex Transm Dis. 1983;10(2):81–84. doi:10.1097/00007435-198304000-00007
   PubMed Web of Science ®Google Scholar
• Herrell WE, Cook EN, Thompson L. Use of penicillin in sulfonamide resistant gonorrheal infections. JAMA. 1943;122(5):289–292. doi:10.1001/jama.1943.02840220021005
   Google Scholar
• Mahoney JF, Ferguson C, Buchholtz M, Van Slyke CJ. The use of penicillin sodium in the treatment of sulfonamide resistant gonorrhea in men. Am J Syph Gonor Ven Dis. 1943;27(5):525–528.
   Google Scholar
• Thayer JD, Field FW, Magnuson HJ, Garson W. The sensitivity of Gonococci to penicillin and its relationship to penicillin failures. Antibiot Chemother. 1957;7(6):306–310.
   Google Scholar
• Martin JE, Lester A, Price EV, Schmale JD. Comparative study of gonococcal susceptibility to penicillin in the United States, 1955–1969. J Infect Dis. 1970;122(5):459–461. doi:10.1093/infdis/122.5.459
   PubMed Web of Science ®Google Scholar
• Jaffe HW, Biddle JW, Thornsberry C, et al. National gonorrhea therapy monitoring study: in vitro antibiotic susceptibility and its correlation with treatment results. N Engl J Med. 1976;294(1):5–9. doi:10.1056/NEJM197601012940102
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommended treatment schedules for gonorrhea - March 1972. Morb Mortal Wkly Rep. 1972;21(10):82.
   Google Scholar
• Boger WP, Beatty JO, Pitts FW, Flippin HF. The influence of a new benzoic acid derivative on the metabolism of para-aminosalicylic acid (PAS) and penicillin. Ann Intern Med. 1950;33(1):18–31.
   PubMed Web of Science ®Google Scholar
• Catlin BW. Probenecid: antibacterial action against Neisseria gonorrhoeae and interaction with benzylpenicillin. Antimicrob Agents Chemother. 1984;25(6):676–682. doi:10.1128/AAC.25.6.676
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 1985 STD treatment guidelines. MMWR Morb Mortal Wkly Rep. 1985;34(Suppl 4):75S–108S.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Sentinel surveillance system for antimicrobial resistance in clinical isolates of Neisseria gonorrhoeae. MMWR Morb Mortal Wkly Rep. 1987;36(35):585–586,591–593.
   Google Scholar
• Centers for Disease Control and Prevention. 1989 Sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep. 1989;38(Suppl 8):1–43.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. 1993 Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep. 1993;42(RR–14):1–102.
   Google Scholar
• Centers for Disease Control and Prevention. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR Recomm Rep. 1998;47(RR–1):1–118.
   Google Scholar
• WHO Western Pacific Region Gonococcal Antimicrobial Surveillance Programme. Surveillance of antimicrobial resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 1999. Commun Dis Intell. 2000;24(9):269–271.
   PubMedGoogle Scholar
• Knapp JS, Neal SW, Parekh MC, Ohye R, Higa H, Rice RJ. Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Honolulu, Hawaii. Antimicrob Agents Chemother. 1994;38(9):2200–2203. doi:10.1128/AAC.38.9.2200
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Fluoroquinolone-resistance in Neisseria gonorrhoeae, Hawaii, 1999, and decreased susceptibility to azithromycin in N. gonorrhoeae, Missouri, 1999. MMWR Morb Mortal Wkly Rep. 2002;49(37):833–837.
   Google Scholar
• Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae --- Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep. 2002;51(46):1041–1044.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep. 2002;51(RR06):1–80.
   Google Scholar
• Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men --- United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep. 2004;53(16):335–338.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Update to CDC’s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007;56(14):332–336.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Morb Mortal Wkly Rep. 2010;59(RR–12):1–110.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012;61(31):590–594.
   PubMedGoogle Scholar
• Allen VG, Seah C, Martin I, Melano RG. Azithromycin resistance is coevolving with reduced susceptibility to cephalosporins in Neisseria gonorrhoeae in Ontario, Canada. Antimicrob Agents Chemother. 2014;58(5):2528–2534. doi:10.1128/AAC.02608-13
   PubMed Web of Science ®Google Scholar
• Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis. 2012;54(6):841–843. doi:10.1093/cid/cir929
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2018. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. Available from: https://www.cdc.gov/std/stats18/STDSurveillance2018-full-report.pdf. Accessed June 19, 2023.
   Google Scholar
• Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65(10):2141–2148. doi:10.1093/jac/dkq289
   PubMed Web of Science ®Google Scholar
• Cyr S S, Barbee L, Workowski KA, et al. Update to CDC’s treatment guidelines for gonococcal infection, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1911–1916. doi:10.15585/mmwr.mm6950a6
   PubMed Web of Science ®Google Scholar
• Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187. doi:10.15585/mmwr.rr7004a1
   PubMed Web of Science ®Google Scholar
• Ong JJ, Bourne C, Dean JA. Australian sexually transmitted infection (STI) management guidelines for use in primary care 2022 update. Sex Health. 2023;20(1):1–8. doi:10.1071/SH22134
   PubMed Web of Science ®Google Scholar
• Public Health Agency of Canada. Sexually transmitted and blood-borne infections: Guides for health professionals. Ottowa, ON: Public Health Agency of Canada; 2023. Available from: https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html. Accessed July 3, 2023.
   Google Scholar
• Unemo M, Ross JDC, Serwin AB, Gomberg M, Cusini M, Jensen JS. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020;1:1–17.
   Google Scholar
• Fifer H, Saunders J, Soni S, Sadiq ST, FitzGerald M. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS. 2020;31(1):4–15. doi:10.1177/0956462419886775
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae. Geneva: World Health Organization; 2016. Available from: https://www.who.int/publications/i/item/9789241549691. Accessed June 16, 2023.
   Google Scholar
• Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587–613. doi:10.1128/CMR.00010-14
   PubMed Web of Science ®Google Scholar
• Unemo M, Del Rio C, Shafer WM. Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiol Spectr. 2016;4(3):10.1128/microbiolspec.EI10-0009–2015.
   PubMed Web of Science ®Google Scholar
• Johnson SR, Morse SA. Antibiotic resistance in Neisseria gonorrhoeae: genetics and mechanisms of resistance. Sex Transm Dis. 1988;15(4):217–224. doi:10.1097/00007435-198810000-00008
   PubMed Web of Science ®Google Scholar
• Averett DR, Roth B, Burchall JJ, Baccanari DP. Dihydrofolate reductase from Neisseria sp. Antimicrob Agents Chemother. 1979;15(3):428–435. doi:10.1128/AAC.15.3.428
   PubMed Web of Science ®Google Scholar
• González N, Gyonne J, Laumen E, et al. Pre-exposure to azithromycin enhances gonococcal resilience to subsequent ciprofloxacin exposure: an in vitro study. F1000Res. 2022;11:1464. doi:10.12688/f1000research.126078.1
   PubMedGoogle Scholar
• Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, Nicholas RA. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009;53(9):3744–3751. doi:10.1128/AAC.00304-09
   PubMed Web of Science ®Google Scholar
• Balduck M, Gyonne J, Laumen E, et al. Tolerance to ceftriaxone in Neisseria gonorrhoeae: rapid Induction in WHO P reference strain and detection in clinical isolates. Antibiotics. 2022;11(11):1480. doi:10.3390/antibiotics11111480
   Google Scholar
• Kueakulpattana N, Wannigama DL, Luk-In S, et al. Multidrug-resistant Neisseria gonorrhoeae infection in heterosexual men with reduced susceptibility to ceftriaxone, first report in Thailand. Sci Rep. 2021;11(1):21659. doi:10.1038/s41598-021-00675-y
   PubMed Web of Science ®Google Scholar
• Handsfield HH, McCutchan JA, Corey L, Ronald AR. Evaluation of new anti-infective drugs for the treatment of uncomplicated gonorrhea in adults and adolescents. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992;15(Suppl 1):S123–S130. doi:10.1093/clind/15.Supplement_1.S123
   PubMedGoogle Scholar
• Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis. 1995;20(Suppl 1):S47–S65. doi:10.1093/clinids/20.Supplement_1.S47
   PubMed Web of Science ®Google Scholar
• Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis. 2007;44(Suppl 3):S84–S101. doi:10.1086/511422
   PubMedGoogle Scholar
• Hook EW, Newman L, Drusano G, et al. Development of new antimicrobials for urogenital gonorrhea therapy: clinical trial design considerations. Clin Infect Dis. 2020;70(7):1495–1500. doi:10.1093/cid/ciz899
   PubMed Web of Science ®Google Scholar
• Handsfield HH, Murphy V. Comparative study of ceftriaxone and spectinomycin for treatment of uncomplicated gonorrhoea in men. Lancet. 1983;322(8341):67–70. doi:10.1016/S0140-6736(83)90058-2
   Google Scholar
• Judson F, Ehret J, Root C. Comparative study of ceftriaxone and aqueous procaine penicillin G in the treatment of uncomplicated gonorrhea in women. Antimicrob Agents Chemother. 1983;23(2):218–220. doi:10.1128/AAC.23.2.218
   PubMed Web of Science ®Google Scholar
• Zajdowicz T, Sanches P, Berg S, Kerbs S, Newquist R, Harrison W. Comparison of ceftriaxone with cefoxitin in the treatment of penicillin-resistant gonococcal urethritis. Sex Transm Infect. 1983;59(3):176–178. doi:10.1136/sti.59.3.176
   Google Scholar
• Judson FN, Ehret JM, Handsfield HH. Comparative study of ceftriaxone and spectinomycin for treatment of pharyngeal and anorectal gonorrhea. JAMA. 1985;253(10):1417–1419. doi:10.1001/jama.1985.03350340069019
   PubMed Web of Science ®Google Scholar
• Panikabutra K, Ariyarit C, Chitwarakorn A, Saensanoh C, Wongba C. Randomised comparative study of ceftriaxone and spectinomycin in gonorrhoea. Sex Transm Infect. 1985;61(2):106–108. doi:10.1136/sti.61.2.106
   Google Scholar
• Dixon CA, Bittiner JB, Shahidullah M, Slack RC, Sulaiman MZ. Randomised observer blind comparative trial of ceftriaxone and penicillin in treating uncomplicated gonorrhoea in men and women. Genitourin Med. 1986;62(2):78–81. doi:10.1136/sti.62.2.78
   PubMedGoogle Scholar
• Baddour LM, Busby L, Shapiro E, Cox KB, Glassco S, Johnson JK. Evaluation of treatment with single-dose ampicillin/sulbactam with probenecid or ceftriaxone in patients with uncomplicated gonorrhea. Sex Transm Dis. 1992;19(6):341–345. doi:10.1097/00007435-199211000-00009
   PubMed Web of Science ®Google Scholar
• McCormack WM, Mogabgab WJ, Jones RB, Wendel JG, Handsfield H. Multicenter, comparative study of cefotaxime and ceftriaxone for treatment of uncomplicated gonorrhea. Sex Transm Dis. 1993;20(5):269–273. doi:10.1097/00007435-199309000-00006
   PubMed Web of Science ®Google Scholar
• de Vries HJC, de Laat M, Jongen VW, et al. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. Lancet Infect Dis. 2022;22:706–717. doi:10.1016/S1473-3099(21)00625-3
   PubMed Web of Science ®Google Scholar
• Ross JDC, Brittain C, Cole M, et al. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet. 2019;393(10190):2511–2520. doi:10.1016/S0140-6736(18)32817-4
   PubMed Web of Science ®Google Scholar
• Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill. 2018;23(27):1800323. doi:10.2807/1560-7917.ES.2018.23.27.1800323
   PubMedGoogle Scholar
• Eyre DW, Town K, Street T, et al. Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Euro Surveill. 2019;24(10):1900147. doi:10.2807/1560-7917.ES.2019.24.10.1900147
   PubMedGoogle Scholar
• Hook EW, Golden MR, Taylor SN, et al. Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, noninferiority, Phase 3, multicenter, randomized study. Sex Transm Dis. 2019;46(5):279–286. doi:10.1097/OLQ.0000000000000971
   PubMed Web of Science ®Google Scholar
• Taylor SN, Morris DH, Avery AK, et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis. 2018;67(4):504–512. doi:10.1093/cid/ciy145
   PubMed Web of Science ®Google Scholar
• Taylor SN, Marrazzo J, Batteiger BE, et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med. 2018;379(19):1835–1845. doi:10.1056/NEJMoa1706988
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2020: Gonococcal Isolate Surveillance Project National Profile. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2022. Available from: https://www.cdc.gov/std/statistics/gisp-profiles/default.htm. Accessed June 16, 2023.
   Google Scholar
• Van Gerwen OT, Muzny CA, Marrazzo JM. Sexually transmitted infections and female reproductive health. Nat Microbiol. 2022;7(8):1116–1126. doi:10.1038/s41564-022-01177-x
   PubMed Web of Science ®Google Scholar
• Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis. 2011;17(1):148–149. doi:10.3201/eid1701.100397
   PubMed Web of Science ®Google Scholar
• Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55(7):3538–3545. doi:10.1128/AAC.00325-11
   PubMed Web of Science ®Google Scholar
• Pleininger S, Indra A, Golparian D, et al. Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. Euro Surveill. 2022;27(24):2200455. doi:10.2807/1560-7917.ES.2022.27.24.2200455
   PubMedGoogle Scholar
• Berçot B, Caméléna F, Mérimèche M, et al. Ceftriaxone-resistant, multidrug-resistant Neisseria gonorrhoeae with a novel mosaic penA-237.001 gene, France, June 2022. Euro Surveill. 2022;27(50):2200899. doi:10.2807/1560-7917.ES.2022.27.50.2200899
   PubMedGoogle Scholar
• Caruso C, Valluzzi RL, Colantuono S, Gaeta F, Romano A. β-Lactam allergy and cross-reactivity: a clinician’s guide to selecting an alternative antibiotic. J Asthma Allergy. 2021;14:31–46. doi:10.2147/JAA.S242061
   PubMed Web of Science ®Google Scholar
• Jani YH, Williams I, Krishna MT. Sustaining and spreading penicillin allergy delabelling: a narrative review of the challenges for service delivery and patient safety. Br J Clin Pharmacol. 2020;86(3):548–559. doi:10.1111/bcp.14190
   PubMed Web of Science ®Google Scholar
• Macy E, Blumenthal KG. Are cephalosporins safe for use in penicillin allergy without prior allergy evaluation? J Allergy Clin Immunol Pract. 2018;6(1):82–89. doi:10.1016/j.jaip.2017.07.033
   PubMed Web of Science ®Google Scholar